Visceral Leishmaniasis Clinical Management in Endemic Districts of India, Nepal, and Bangladesh
Table 1
VL case management: patient experiences.
India
Nepal
Bangladesh
Overall
2009
2010
2009
2010
2009
2010
2009
2010
No. of new VL cases detected
63
8
8
20
212
13
92
41
No. of VL cases started with (%)
(i) SAG
34/63 (54%)
1/8 (13%)
0/8 (0%)
0/20 (0%)
8/8 (100%)
0/13 (0%)
42/79 (53%)
1/41 (2%)
(ii) Amphotericin B
6/63 (10%)
0/8 (0%)
5/8 (63%)
16/20 (80%)
0/8 (0%)
0/13 (0%)
11/79 (14%)
16/41 (39%)
(iii) Miltefosine
23/63 (37%)
7/8 (88%)
3/8 (38%)
4/20 (20%)
0/8 (0%)
13/13 (100%)
26/79 (33%)
24/41 (59%)
No. of VL cases given correct dosage schedule (%)
62/63 (98%)
8/8 (100%)
3/3 (100%)
20/20 (100%)
8/8 (100%)
13/13 (100%)
73/74 (99%)
41/41 (100%)
No. of VL cases with treatment interrupted (%)
1/63 (2%)
1/8 (13%) (side effect)
0/3 (0%)
1/20 (5%) (no drug)
0/8 (0%)
0/13 (0%)
1/74 (1%)
2/41 (5%)
No. VL cases experiencing side effects (%)
2/63 (3%)
1/8 (13%)
0/3 (0%)
1/20 (5%)
0/8 (0%)
2/13 (15%)
2/74 (3%)
4/41 (10%)
No. VL cases received doctor’s advice on (%)
(i) Need to comply with treatment (%)
63/63 (100%)
8/8 (100%)
3/3 (100%)
20/20 (100%)
—3
13/13 (100%)
66/66 (100%)
41/41 (100%)
(ii) Side effects (%)
2/63 (3%)
8/8 (100%)
3/3 (100%)
6/20 (30%)
—2
12/13 (92%)
5/66 (8%)
26/41 (63%)
(iii) Compliance with follow up (%)
37/63 (59%)
8/8 (100%)
3/3 (100%)
11/20 (55%)
—2
12/13 (92%)
40/66 (61%)
31/41 (76%)
Did you comply with FU advise
37/63 (59%)
8/8 (100%)
3/3 (100%)
7/20 (35%)
—2
12/13 (92%)
40/66 (61%)
27/41 (66%)
Volunteer support for home treatment with Miltefosine (%)
15/23 (65%)
4/7 (57%)
3/3 (100%)
3/4 (75%)
NA4
4/13 (31%)
18/26 (69%)
11/24 (46%)
213 patients were diagnosed as relapse of VL and referred to district hospital. Treatment status could not be ascertained subsequently. 3Information on doctor advice to patients is not captured in Bangladesh in the interview for patients who received other than Miltefosine treatment. 4Not applicable as no patient received Miltefosine.
